Archive for the ‘Pharma Industry’ Category

August 6, 2011

Reviews from the Industry by Joachim Greuel

Written on August 6, 2011 by blended.team in MBM News, News, Pharma Industry

Reviews from the Industry: Today, our academic director Joachim Greuel sets the focus on Biotech Stocks and the relevance of pricing decisions in the Companies.

 Biotech Stocks Vulnerable to Economic Concerns 

Biotech Stocks

 Last Thursday, 4 August 2011 the NASDAQ Biotechnology and the AMEX Biotechnology indices lost 8% and 11%, respectively, while the AMEX Pharmaceutical index fell only 4%. The last time a similar downturn was observed was in 2008.

This demonstrates, once more, that biotech stocks with highly volatile cash flows are more vulnerable to the general economic environment than stocks of more established firms.

While this may not come as a surprise, some biotech companies suffer more from general market conditions than others.

As a consequence, management should design strategies to minimize volatility as much as possible, also in order to reduce its cost of capital.

 In our MBM courses we will discuss strategies how this may be accomplished.

Dendreon Falls 67% After Lower Than Expected Provenge Sales

Dendreon Case

 Last  Thursday, 4 August 2011, Dendreon stock fell 67% (by $24.15 to $11.69) after the company reported a lower than expected uptake of its recently (April 2010) approved cancer cell therapy Provenge.

As Provenge is the first available autologous cellular immunotherapy against cancer worldwide, the stock has received significant attention. It is believed that the therapy’s high price prevents a rapid market penetration. Although the US federal agency CMS has determined that Medicare will reimburse the therapy that costs over $90,000.-, the therapy’s cost-effectiveness has been questioned as it extends life by no more than four months, on average.

The Dendreon case demonstrates the importance of  pricing decisions: innovative therapies that do not demonstrate a clear cost-effectiveness will penetrate the market much slower than they would with a shown, undisputable pharmacoeconomic benefit. Thus, pricing decisions are no longer solely driven by market studies such as conjoint analyses, but also by outcomes research. Biotech managers that often tend to focus on R&D should think about pharmacoeconomics; the likelihood of a good licensing deal, for example, also depends on pharmacoeconomic aspects 

July 12, 2011

Success Story!

Written on July 12, 2011 by blended.team in Careers, MBM News, Pharma Industry

Our alumni ATSUSHI SHIMADA  of the Master in Biotechnology Management  2010

shares his successful career upgrade at TAKEDA Pharmaceuticals… 

Hi everybody!ATSUSHI SHIMADA

Mi name is Atsushi Shimada and now I can proudly say that I am the Business Development Manager in Singapore for TAKEDA Pharmaceuticals.

Actually, after the master, I was not only earlier promoted to the manager’s position but also elected to a global career development program which could prepare me for a potential senior or top management position.  At this program, I will have a two-year residence period in any one of our companies’ subsidiaries in the world where I am going to experience business development, marketing, finance, business intelligence, etc. 

This was possible after requesting our company to send me to the representative successful biotech company, about which we had a class in the strategy course.  I was so lucky since only two persons among 10,000 employees in our company can be nominated to this program per year and I am one of the two!!  I think all these luck comes from my study at IE Master in Biotechnology Management!!! 

I very much appreciate it.

July 5, 2011

Motivational Text Messages May Help Smokers Quit *

Text2Stop

Motivational text messages more than double the odds that smokers will be able to kick the habit, new research suggests.

The study included 5,800 smokers in the United Kingdom who wanted to quit and were assigned to either a group who received motivational text messages (2,915 participants) or a control group who received non-motivational text messages (2,885 participants).

The motivational messages sent to those in the so-called txt2stop group included encouragement, help dealing with cravings, and advice on preventing weight gain while quitting smoking. For example, the message about cravings said: “Cravings last less than 5 minutes on average. To help distract yourself, try sipping a drink slowly until the craving is over.”

The non-motivational messages said things not connected to the study, such as thanking people for taking part or asking for confirmation of contact details, according to the report published online June 29 in The Lancet.

The participants’ saliva was tested to verify quit rates. Those who received motivational messages were more than twice as likely to quit as those in the control group — 10.7 percent versus 4.9 percent. The findings suggest that motivational texting should be added to existing techniques used to help people quit smoking, concluded Dr. Caroline Free, of the London School of Hygiene and Tropical Medicine, and colleagues.

“Text messages are a very convenient way for smokers to receive support to quit. People described txt2stop as like having a ‘friend’ encouraging them or an ‘angel on their shoulder.’ It helped people resist the temptation to smoke,” Free said in a journal news release.

The American Cancer Society offers a guide to quitting smoking.

* Article from Drugs Information Online Drugs.com 

June 17, 2011

Marketing & Sales for the Biomedical Market

Written on June 17, 2011 by blended.team in MBM News, Pharma Industry

The Novartis Case, developed at IE Business School by our students  and conducted by Professor Claire Bastien has been awarded at the European Foundation in Management Development case writing competition.

This interactive case study has been developed for students to apply their knowledge about how to develop a sales strategy and a commercial plan. It takes a practical approach and includes two interactive exercises that simulate the strategy set by students based on Novartis Spain challenges in 2008.

May 19, 2011

Working as a Brand Manager for one of the leader firms in the Pharmaceutical industry, Shigeo decided to take the Master in Biotechnology Management.
In this video he explains why he chose this particular blended program.

We use both our own and third-party cookies to enhance our services and to offer you the content that most suits your preferences by analysing your browsing habits. Your continued use of the site means that you accept these cookies. You may change your settings and obtain more information here. Accept